Publications by authors named "A M Al-Katib"
Background: PNT2258 is a liposomal formulation that encapsulates multiple copies of PNT100, a native, chemically unmodified, 24-base DNA oligonucleotide designed to target the regulatory region upstream of the B-cell lymphoma 2 (BCL2) gene.
Methods: This phase II, multicenter, single-arm, open-label, 2-stage design study investigated the single-agent activity of PNT2258 in patients with relapsed/refractory DLBCL. Initially, patients had to have a performance status (PS) of ≤2 and prior exposure to CD20-targeted therapy, an alkylating agent, and a steroid with no upper limit.
A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-Cell Malignancies.
Clin Lymphoma Myeloma Leuk
December 2021
Background: PNT2258 consists of a native, chemically unmodified, 24-base DNA oligonucleotide designed to target the regulatory region upstream of the BCL2 gene, delivered in a protective liposome. Derangement of BCL2-regulated control mechanisms is a defining characteristic of certain malignancies, and it was hypothesized that the oligonucleotide would promote anticancer activity via suppression of BCL2 transcription.
Methods: PNT2258 was evaluated in this, multicenter, nonrandomized, open-label Phase 2 study in 13 participants with relapsed/refractory B-cell malignancies to investigate potential antitumor activity and safety.
Article Synopsis
- COVID-19 has led to a unique coagulopathy known as COVID-19-induced coagulopathy (CIC), characterized by high levels of D-dimer and fibrin split products, while traditional coagulation tests show minimal changes.
- CIC is distinct from sepsis-induced coagulopathy and involves a severe cytokine storm, resulting in significant blood clotting issues and organ damage.
- A proposed scoring system for CIC aims to guide anticoagulation therapy based on patient risk categories, with the understanding that guidelines will evolve as more research is conducted.
Article Synopsis
- Ibrutinib is approved for treating chronic lymphocytic leukemia (CLL) but its effectiveness for multiple myeloma (MM) is still under research.
- A case study showed a patient with CLL developed MM while being treated with ibrutinib.
- This suggests that ibrutinib may not be effective in treating multiple myeloma.
Non-Hodgkin's lymphoma (NHL) is the most common hematological malignancy in the US. Many types remain incurable despite response to initial therapy and achievement of complete remission (CR). Advanced laboratory techniques like multicolor flow cytometry (FCM) and polymerase chain reaction (PCR) have demonstrated persistence of rare malignant cell population post therapy.
View Article and Find Full Text PDF